Supplementary Table S3 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
Year: 2025
Type: supplementary-materials
Abstract: Table S3 shows the demographics of the randomized population for Study 20120215.
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4415212160
